<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73809">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827943</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-08</org_study_id>
    <nct_id>NCT01827943</nct_id>
  </id_info>
  <brief_title>Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer</brief_title>
  <acronym>VESTOR</acronym>
  <official_title>Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the absence of standard treatment in this indication, this test evaluates a new drug type
      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the absence of standard treatment in this indication, this test evaluates a new drug type
      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and
      survival. This study will also search for genes involved in the response to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of the efficacy of Temsirolimus (Torisel ®) in terms of non-progression rate (PR+CR+SD) after 2 months of treatment</measure>
    <time_frame>12/2013 (2 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the efficacy of Temsirolimus (Torisel ®) in terms of non-progression rate (PR+CR+SD) after 2 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Progression free survival  • Duration of response • Time to progression • Overall survival • Quality of life</measure>
    <time_frame>12/2013 (2 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival
Duration of response
Time to progression
Overall survival
Quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Relapsed Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>TORISEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torisel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TORISEL</intervention_name>
    <description>Temsirolimus</description>
    <arm_group_label>TORISEL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of at least 18 years of age

          -  Histologically proven Bladder cancer

          -  Locally advanced or metastatic disease (stage IV)

          -  Functional status (ECOG / OMS) ≤ 2

          -  Relapse after first-line chemotherapy

          -  Measurable lesions (RECIST criteria)

          -  Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.

          -  Biological levels :

          -  Neutrophil count &gt;1,5.109/L.

          -  Platelets &gt;100.109/L

          -  Total serum bilirubin &lt; 1.5 × ULN

          -  Clearance of créatinine 40 ml/mm

          -  If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) &lt;2.5 × ULN

          -  With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;5 ×
             ULN

          -  Signed informed consent France only : Patients affiliated to a social security
             program

        Exclusion Criteria:

          -  Presence of uncontrolled metastatic brain or meningeal tumours

          -  Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion

          -  Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or
             polysorbate 80 or to their excipients

          -  Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma
             curatively treated) or incidental (≤ pT2) prostate cancer found on a radical
             cystoprostatectomy material

          -  Auto-immune pathology, psychiatric or neurological disorder

          -  Any unstable medical condition

          -  Unstable cardiac disease

          -  Severe renal failure

          -  Unstable diabetes

          -  Pregnancy

          -  Patient enrolled in another therapeutic clinical trial

          -  Patient unable to follow and comply with the study procedures because of any
             geographical, social or medical condition

          -  Patient partially or totally deprived of his civil rights
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine HOUEDE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadine HOUEDE, MD</last_name>
    <phone>0556333333</phone>
    <email>houede@bergonie.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, PU-PH</last_name>
    <phone>0556333333</phone>
    <email>mathoulin@bergonie.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé WALLERAND</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakim Mahammedi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CULINE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des armées du Val-de-Grâce</name>
      <address>
        <city>Paris</city>
        <zip>75230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel VEDRINE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian PFISTER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard MALAVAUD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.bergonie.org/fr/essais-clinique.html</url>
    <description>Institut Bergonié</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 9, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed bladder cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
